What treatments are available for liver metastatic uveal melanoma patients?
For patients with uveal melanoma that has spread to the liver, several treatment options are available. The choice depends on factors like the patient's HLA type, extent of liver involvement, and prior treatments. A 2024 network meta-analysis found that combining liver-directed therapy (such as immunoembolization or radiation) with immune checkpoint inhibitors (ICIs) may offer the best overall survival and progression-free survival 1. Tebentafusp, a targeted immunotherapy, is approved for patients who carry the HLA-A*02:01 gene and has shown improved survival compared to other systemic therapies 145.
What the research says
A network meta-analysis of 16 trials involving 2,585 patients compared eight treatment approaches for liver metastatic uveal melanoma 1. The combination of liver-directed therapy (LDT) plus immune checkpoint inhibitors (ICIs) ranked best for both overall survival (OS) and progression-free survival (PFS). Tebentafusp showed the second-best OS but the worst PFS among the treatments studied. ICIs alone were less effective than tebentafusp for OS but better for PFS 1. These results suggest that combining local liver treatments with systemic immunotherapy may provide the greatest benefit.
Tebentafusp is a bispecific protein that redirects T cells to kill cancer cells expressing gp100, and it is only effective in patients who are HLA-A*02:01 positive 245. A phase 2 trial (N=378) compared tebentafusp to investigator's choice of dacarbazine, ipilimumab, or pembrolizumab in previously untreated advanced uveal melanoma, with overall survival as the primary endpoint 4. Tebentafusp improved survival and became the first FDA-approved systemic therapy for metastatic uveal melanoma 5. However, durable responses remain uncommon, and combining tebentafusp with other treatments may help. A case report described a patient who progressed on tebentafusp alone but achieved a durable partial response when stereotactic body radiotherapy (SBRT) was added to the nodal site while continuing tebentafusp, with disease control lasting over 35 months 2.
Liver-directed therapies are a mainstay for patients with liver-dominant disease. These include surgical resection, radioembolization, chemoembolization, immunoembolization, isolated hepatic perfusion, and thermal ablation 67. A retrospective study of 43 patients treated with immunoembolization (IE) reported a disease control rate (DCR) of 72.1%, with median overall survival of 18.5 months 3. However, the DCR was lower than that reported in the phase 3 FOCUS trial of melphalan via percutaneous hepatic perfusion, suggesting that other regional therapies may offer better short-term control 3. The study also noted that patients who received prior systemic therapy had worse outcomes, indicating that earlier use of liver-directed therapy might be beneficial 3.
Despite these advances, metastatic uveal melanoma remains a challenging disease with a median overall survival of 6 to 12 months once liver metastases develop 6. There is no single standard of care, and clinical trials continue to explore new combinations and approaches 7. Patients should discuss with their oncologist the best option based on their specific situation, including HLA status, tumor burden, and prior treatments.
What to ask your doctor
- Am I HLA-A*02:01 positive, and would tebentafusp be an option for me?
- Could I benefit from a combination of liver-directed therapy (like immunoembolization or radiation) with immunotherapy?
- Are there any clinical trials available for my specific situation?
- What are the potential side effects of the recommended treatment, and how are they managed?
- How will we monitor my response to treatment, and what are the next steps if the disease progresses?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.